tetano
Editor, Senior Moderator
Vaccine. 2015 Apr 24. pii: S0264-410X(15)00512-5. doi: 10.1016/j.vaccine.2015.04.048. [Epub ahead of print]
[h=1]Safety of Russian-backbone seasonal trivalent, live-attenuated influenza vaccine in a phase II randomized placebo-controlled clinical trial among children in urban Bangladesh.[/h] Ortiz J[SUP]1[/SUP], Goswami D[SUP]2[/SUP], Lewis KD[SUP]3[/SUP], Sharmeen AT[SUP]2[/SUP], Ahmed M[SUP]2[/SUP], Rahman M[SUP]2[/SUP], Rahman MZ[SUP]2[/SUP], Feser J[SUP]3[/SUP], Neuzil KM[SUP]4[/SUP], Brooks WA[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]INTRODUCTION:[/h] Live-attenuated influenza vaccines (LAIVs) have the potential to be affordable, effective, and logistically feasible for immunization of children in low-resource settings.
[h=4]MATERIAL AND METHODS:[/h] We conducted a phase II, randomized, double-blind, parallel group, placebo-controlled trial on the safety of the Russian-backbone, seasonal trivalent LAIV among children aged 24 through 59 months in Dhaka, Bangladesh in 2012. After vaccination, we monitored participants for six months with weekly home visits and study clinic surveillance for solicited and unsolicited adverse events, protocol-defined wheezing illness (PDWI), and serious adverse events (SAEs), including all cause hospitalizations.
[h=4]RESULTS:[/h] Three hundred children were randomized and administered LAIV (n=150) or placebo (n=150). No immediate post-vaccination reactions occurred in either group. Solicited reactions were similar between vaccine and placebo groups during the first 7 days post-vaccination and throughout the entire trial. There were no statistically significant differences in participants experiencing PDWI between LAIV and placebo groups throughout the trial (n=13 vs. n=16, p=0.697). Of 131 children with a history of medical treatment or hospitalization for asthma or wheezing at study entry, 65 received LAIV and 66 received placebo. Among this subset, there was no statistical difference in PDWI occurring throughout the trial between the LAIV or placebo groups (7.7% vs. 19.7%, p=0.074). While there were no related SAEs, LAIV recipients had six unrelated SAEs and placebo recipients had none. These SAEs included three due to traumatic injury and bone fracture, and one each due to accidental overdose of paracetamol, abdominal pain, and acute gastroenteritis. None of the participants with SAEs had laboratory-confirmed influenza, wheezing illness, or other signs of acute respiratory illness at the time of their events.
[h=4]CONCLUSIONS:[/h] In this randomized, controlled trial among 300 children aged 24 through 59 months in urban Bangladesh, Russian-backbone LAIV was safe and well tolerated. Further evaluation of LAIV safety and efficacy in a larger cohort is warranted.
Copyright ? 2015. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Clinical trial; Live attenuated influenza vaccine
PMID: 25917680 [PubMed - as supplied by publisher]
[h=1]Safety of Russian-backbone seasonal trivalent, live-attenuated influenza vaccine in a phase II randomized placebo-controlled clinical trial among children in urban Bangladesh.[/h] Ortiz J[SUP]1[/SUP], Goswami D[SUP]2[/SUP], Lewis KD[SUP]3[/SUP], Sharmeen AT[SUP]2[/SUP], Ahmed M[SUP]2[/SUP], Rahman M[SUP]2[/SUP], Rahman MZ[SUP]2[/SUP], Feser J[SUP]3[/SUP], Neuzil KM[SUP]4[/SUP], Brooks WA[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]INTRODUCTION:[/h] Live-attenuated influenza vaccines (LAIVs) have the potential to be affordable, effective, and logistically feasible for immunization of children in low-resource settings.
[h=4]MATERIAL AND METHODS:[/h] We conducted a phase II, randomized, double-blind, parallel group, placebo-controlled trial on the safety of the Russian-backbone, seasonal trivalent LAIV among children aged 24 through 59 months in Dhaka, Bangladesh in 2012. After vaccination, we monitored participants for six months with weekly home visits and study clinic surveillance for solicited and unsolicited adverse events, protocol-defined wheezing illness (PDWI), and serious adverse events (SAEs), including all cause hospitalizations.
[h=4]RESULTS:[/h] Three hundred children were randomized and administered LAIV (n=150) or placebo (n=150). No immediate post-vaccination reactions occurred in either group. Solicited reactions were similar between vaccine and placebo groups during the first 7 days post-vaccination and throughout the entire trial. There were no statistically significant differences in participants experiencing PDWI between LAIV and placebo groups throughout the trial (n=13 vs. n=16, p=0.697). Of 131 children with a history of medical treatment or hospitalization for asthma or wheezing at study entry, 65 received LAIV and 66 received placebo. Among this subset, there was no statistical difference in PDWI occurring throughout the trial between the LAIV or placebo groups (7.7% vs. 19.7%, p=0.074). While there were no related SAEs, LAIV recipients had six unrelated SAEs and placebo recipients had none. These SAEs included three due to traumatic injury and bone fracture, and one each due to accidental overdose of paracetamol, abdominal pain, and acute gastroenteritis. None of the participants with SAEs had laboratory-confirmed influenza, wheezing illness, or other signs of acute respiratory illness at the time of their events.
[h=4]CONCLUSIONS:[/h] In this randomized, controlled trial among 300 children aged 24 through 59 months in urban Bangladesh, Russian-backbone LAIV was safe and well tolerated. Further evaluation of LAIV safety and efficacy in a larger cohort is warranted.
Copyright ? 2015. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Clinical trial; Live attenuated influenza vaccine
PMID: 25917680 [PubMed - as supplied by publisher]